key: cord-0731854-moys14wi
authors: Yan, Di; Kolla, Avani M.; Young, Trevor; Fried, Lauren; Shankar, Shruthi; Rangel, Lauren; Yin, Lu; Castillo, Rochelle; Steuer, Alexa; Svigos, Katerina; Izmirly, Peter; Sekar, Vaish; Lesser, Robert; Solomon, Gary; Blank, Rebecca B.; Haberman, Rebecca H.; Neimann, Andrea L.; Scher, Jose U.
title: COVID-19 outcomes in patients with psoriasis and psoriatic arthritis: A prospective cohort study
date: 2022-03-28
journal: JAAD Int
DOI: 10.1016/j.jdin.2022.03.011
sha: 3f66632f8498dfaccf73685d3d2c473caa0aa733
doc_id: 731854
cord_uid: moys14wi

nan

J o u r n a l P r e -p r o o f Few studies have directly investigated the effects of psoriatic disease and the use of 39 immunomodulatory therapies on COVID-19 outcomes. Here, we report the COVID-19 outcomes 40 of patients with psoriatic disease from the multidisciplinary, prospective cohort WARCOV study 41 (Web-based Assessment of Autoimmune, Immune-Mediated, and Rheumatic Patients during the 42 COVID-19 Pandemic) 1 . 43 44 173 adults with psoriasis (PsO) and/or psoriatic arthritis (PsA) were recruited from NYU Langone 45

Health (IRB#i20-00389) and the NYC Health + Hospitals/Bellevue (IRB#STUDY00002387), and 46 followed from March to July 2020. Participants were referred by a dermatologist or rheumatologist 47 or had previously consented to be contacted for research purposes. Pairwise t-test and Fisher's 48 exact/Chi square test were used to compare demographic and clinical characteristics. Adjusted 49 logistic regression models were used to assess the effect of comorbidities and immunomodulatory 50 therapies on COVID-19 outcomes. Statistical analyses were conducted using R, version 3.6.1. 51 52 Fifty-eight (33.5%) patients (40 confirmed; 18 high suspicion) contracted COVID-19 Most 53 patients (81%) who developed COVID-19 had mild disease (managed at home or in an outpatient 54 setting). Eleven patients (19%) were hospitalized for severe disease, including 4 (6.9%) patients 55 who were treated on the floor and 6 patients (10%) who required intensive care. Four patients died 56 from COVID-19 related complications (6.9%). All four patients had pre-existing risk factors for 57 severe infection and two had high-risk exposures to a healthcare setting. There was no significant 58 difference in age, gender, ororunderlying psoriatic disease between controls, cases, or those who 59 had severe COVID-19 ( Table 1) . 

COVID-19 in Patients With Inflammatory 91 Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying

93 2. Health N. COVID-19: data

Severe COVID-19 outcomes in patients with 95 psoriasis

Biologics increase the risk of SARS-CoV-2 97 infection and hospitalization, but not ICU admission and death: Real-life data from a 98 large cohort during red-zone declaration

National Psoriasis Foundation COVID-19 Task 100 Force guidance for management of psoriatic disease during the pandemic: Version 2-101 Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 102 treatments